| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $4,848,279 ) |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01ES034250 | STAG2 modulates environmental toxicant exposures and epigenomic heterogeneity | 000 | 4 | NIH | 12/11/2024 | $597,213 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA285707 | Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer | 000 | 1 | NIH | 12/16/2024 | $719,799 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA250412 | Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity | 000 | 5 | NIH | 12/18/2024 | $627,451 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA258337 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | 000 | 4 | NIH | 12/24/2024 | $572,254 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01HL150266 | Inhibition of Radiation-Induced Coronary Microvascular Disease | 000 | 5 | NIH | 12/10/2024 | $411,136 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA266216 | Induction of interferon response by chromatin damaging anti-cancer therapy | 000 | 2 | NIH | 11/25/2024 | $357,193 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 000 | 3 | NIH | 11/27/2024 | $466,991 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA243456 | Radiogenomic Credentialing of Head and Neck Cancer Models | 000 | 5 | NIH | 11/25/2024 | $517,298 |
| | 2025 | 2025 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 000 | 5 | NIH | 11/25/2024 | $345,191 |
| | 2025 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R35GM148071 | The Genetic Basis of Human DNA Replication Timing | 001 | 2 | NIH | 1/13/2025 | $76,340 |
| | 2025 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA286765 | Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL | 003 | 2 | NIH | 12/23/2024 | -$6,856 |
| | 2025 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA286765 | Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL | 001 | 2 | NIH | 12/20/2024 | $179,046 |
| | 2025 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 000 | 1 | NIH | 12/20/2024 | -$14,777 |
| | 2025 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | P50CA159981 | Roswell Park Ovarian Cancer SPORE | 000 | 10 | NIH | 12/6/2024 | $0 |
| | 2025 | 2023 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA237027 | Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPC | 000 | 5 | NIH | 12/13/2024 | $0 |
| | 2025 | 2023 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R50CA221786 | Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation | 000 | 5 | NIH | 12/17/2024 | $0 |
| | 2025 | 2022 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA130995 | Replication Licensing in Genome Stability, Cancer and Aging | 000 | 15 | NIH | 11/20/2024 | $0 |
| | 2025 | 2022 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA256321 | Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer | 000 | 2 | NIH | 10/29/2024 | $0 |
| | 2025 | 2022 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA256537 | Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic Therapy | 000 | 2 | NIH | 10/17/2024 | $0 |
| | 2025 | 2021 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA211912 | Regulation of non-proteolytic ubiquitination in cancer chemoresistance and progression | 000 | 5 | NIH | 11/6/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $49,541,440 ) (Continued on the next page) |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03CA289559 | Linking lifestyles with tumor immune profiles to identify strategies for improving breast cancer outcomes | 000 | 1 | NIH | 3/1/2024 | $86,750 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA292639 | Targeting retrotransposons for improved treatment of refractory childhood cancer | 000 | 1 | NIH | 6/5/2024 | $602,486 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 001 | 4 | NIH | 4/15/2024 | $19,178 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R37CA248018 | Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | 000 | 4 | NIH | 11/8/2023 | $345,207 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA255242 | Advancing skin cancer prevention by tackling UV-induced clonogenic mutations | 001 | 4 | NIH | 4/17/2024 | $29,904 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA255242 | Advancing skin cancer prevention by tackling UV-induced clonogenic mutations | 000 | 4 | NIH | 1/19/2024 | $538,310 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R35GM148071 | The Genetic Basis of Human DNA Replication Timing | 002 | 2 | NIH | 6/21/2024 | $45,804 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R35GM148071 | The Genetic Basis of Human DNA Replication Timing | 001 | 2 | NIH | 12/18/2023 | $412,236 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 001 | 1 | NIH | 9/9/2024 | -$49,202 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 000 | 1 | NIH | 12/6/2023 | $86,750 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K12CA279869 | Preparing Nurse Scientists to Lead the Future of Oncology Research | 000 | 1 | NIH | 8/9/2024 | $55,296 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA279766 | Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer | 001 | 1 | NIH | 6/3/2024 | $290 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | K08CA279766 | Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancer | 000 | 1 | NIH | 5/31/2024 | $314,043 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | F30CA284763 | Understanding the role of β2AR-signaling on ILC2 differentiation/plasticity and its implications in cancer progression | 000 | 2 | NIH | 8/7/2024 | $33,792 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA275081 | Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment | 000 | 2 | NIH | 6/20/2024 | $479,955 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R21CA286342 | Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer | 000 | 1 | NIH | 5/30/2024 | $460,977 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01DA057228 | Assessing pharmacokinetic and pharmacodynamic variability of Δ9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine | 001 | 3 | NIH | 6/21/2024 | $666,413 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA282430 | Novel synthetic lethality strategy for TP53 mutant colorectal cancer | 000 | 2 | NIH | 8/1/2024 | $502,520 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01HL167232 | Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation | 002 | 2 | NIH | 7/31/2024 | -$14,471 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01HL167232 | Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation | 001 | 2 | NIH | 4/25/2024 | $723,500 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA272771 | The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer | 001 | 2 | NIH | 4/17/2024 | $21,699 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA272771 | The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer | 000 | 2 | NIH | 3/5/2024 | $390,585 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA281862 | A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors | 000 | 2 | NIH | 8/12/2024 | $735,428 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01CA278802 | TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors | 000 | 2 | NIH | 4/30/2024 | $677,410 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | ELM & CARLTON ST | BUFFALO | NY | 14263-0001 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 000 | 2 | NIH | 1/9/2024 | $425,943 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R37CA275961 | Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma | 001 | 2 | NIH | 4/17/2024 | $23,664 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R01MD016850 | Implementation of evidence-based strategies to optimize HPV vaccination in rural primary care settings | 000 | 3 | NIH | 5/1/2024 | $665,986 |
| | 2024 | 2024 | HEALTH RESEARCH, INC. | 665 ELM ST | BUFFALO | NY | 14203-1104 | ERIE | USA | R03CA280307 | The role of ceramide kinase in metastasis growth from aggressive breast cancer | 000 | 2 | NIH | 4/16/2024 | $86,750 |
|
